Key result
Above-median TTR linked to ~56% lower mortality in mechanical heart valve patients.
Why the study?
Mechanical prosthetic heart valves are commonly used, but few longitudinal data on the specific causes of hospitalization in these patients are available.
Observational (n=305)
No
Patients with mechanical prosthetic heart valves face high rates of cardiovascular hospitalization and death, but maintaining high time in therapeutic range for anticoagulation significantly reduces mortality risk.
High hospitalization rates persist among mechanical valve patients; high TTR was associated with lower mortality but leaves optimal management open for prospective trials.
Mechanical prosthetic heart valves (MPHVs) are commonly used for valvular heart disease in patients with a long life expectancy. Few longitudinal data on the specific causes of hospitalization in patients with MPHV are available. We investigated the risk of all-cause hospitalization and mortality in patients with MPHV. We performed a prospective, observational, ongoing study including consecutive patients with MPHVs who were referred to the atherothrombosis outpatient clinic of the Policlinico Umberto I of Rome for the vitamin K antagonist management. Study end points were all-cause, cardiovascular hospitalization, and overall mortality. We included 305 patients with MPHV (38.4% women, median age 60.2 years). The site of MPHV was aortic in 53.5%, mitral in 29.5%, and mitroaortic in 17%. During a median follow-up of 57.3 months, 142 hospitalizations occurred (8.16 per 100 person-years). The most common causes of hospitalization were cardiovascular disease (3.62 per 100 person-years), infections, surgery, and bleeding. The predictors of cardiovascular hospitalization were atrial fibrillation (hazard ratio [HR] 1.75, 95% confidence interval [CI] 1.04 to 2.95, p = 0.035), previous stroke/transient ischemic attack (HR 2.96, 95% CI 1.59 to 5.48, p = 0.001), and peripheral artery disease (HR 2.42, 95% CI 1.09 to 5.36, p = 0.030). During a median follow-up of 97.2 months, 61 deaths occurred (2.43 per 100 person-years). Age was directly associated with the risk of death (HR 1.088, 95% CI 1.054 to 1.122, p <0.001), whereas the time in therapeutic range higher than the median was inversely associated (HR 0.436, 95% CI 0.242 to 0.786, p = 0.006). In conclusion, patients with MPHV had a high incidence of hospitalizations, especially cardiovascular-related. The incidence of death is high; however, it may be decreased by maintaining a good quality of anticoagulation.
No takes yet. Share an insight, caveat, or question.
Palumbo et al. (2024) conducted an observational in Mechanical prosthetic heart valves (n=305). Vitamin K antagonist management was evaluated on All-cause, cardiovascular hospitalization, and overall mortality. Patients with mechanical prosthetic heart valves had 8.16 hospitalizations per 100 person-years; time in therapeutic range above the median reduced mortality (HR 0.436; 95% CI 0.242-0.786).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: